Zobrazeno 1 - 10 of 50 pro vyhledávání: '"J. S. Zielonka"'
1
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
Autor: Thomas Blevins, Steve Edelman, R. A. Ortmann, Timothy M. Costigan, Melvin J. Prince, J. S. Zielonka, Mark A. Deeg, Robert J. Konrad, Liza L. Ilag, Robyn K. Pollom, W. J. Huster, Priscilla Hollander
Publikováno v: Diabetes, Obesity & Metabolism
Aims To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), products with identical primary amino acid sequences, in patients with type 1 o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7cd1d91c5af5483c4f4d9e304aab47
http://europepmc.org/articles/PMC4737399
Zobrazit plný text záznamu
2
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( L antus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
Autor: W. J. Huster, Liza L. Ilag, Julio Rosenstock, D. Dahl, Thomas Blevins, Robyn K. Pollom, J. S. Zielonka, Melvin J. Prince
Publikováno v: Diabetes, Obesity and Metabolism. 17:726-733
Aims To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D). Methods This phase III, randomized, open-label, 52-week study enrol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0d0c0ad64c596bab70b26c39d749887
https://doi.org/10.1111/dom.12496
Zobrazit plný text záznamu
3
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( L antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)
Autor: Robyn K. Pollom, Liza L. Ilag, Julio Rosenstock, J. S. Zielonka, Priscilla Hollander, Melvin J. Prince, Anuj Bhargava, W. J. Huster
Publikováno v: Diabetes, Obesity and Metabolism. 17:734-741
Aims To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D). Methods Thi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dfb5347406bc2fb59ea43f7faff6e254
https://doi.org/10.1111/dom.12482
Zobrazit plný text záznamu
7
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
Autor: T C, Blevins, D, Dahl, J, Rosenstock, L L, Ilag, W J, Huster, J S, Zielonka, R K, Pollom, M J, Prince
Publikováno v: Diabetes, obesitymetabolism. 17(8)
To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D).This phase III, randomized, open-label, 52-week study enrolled patients w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3ea1fc86a1bc96fccc44807fa91e8df4
https://pubmed.ncbi.nlm.nih.gov/25974640
Zobrazit plný text záznamu
8
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
Autor: J, Rosenstock, P, Hollander, A, Bhargava, L L, Ilag, R K, Pollom, J S, Zielonka, W J, Huster, M J, Prince
Publikováno v: Diabetes, obesitymetabolism. 17(8)
To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus(®)) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D).This phase III,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f4fbe495567f22e46efc79e32f460218
https://pubmed.ncbi.nlm.nih.gov/25931141
Zobrazit plný text záznamu
9
CA-022: Efficacité et tolérance de LY2963016 chez des patients atteints de diabète de type 1 et 2 traités antérieurement par l'insuline glargine
Autor: LB Lacaya, Liza L. Ilag, J. S. Zielonka, Roy Daniel Pollom, D. Dahl, I. Benabbad, Irene Hadjiyianni
Publikováno v: Diabetes & Metabolism. 42:A40-A41
Objectif Evaluer l'effet d'un traitement par LY2963016 insuline glargine (LY IGlar) compare a l'insuline glargine (Sanofi-Aventis ; IGlar) dans un sous-groupe de patients anterieurement traites par IGlar (IGlar anterieur) pour un diabete de type 1 da
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2fc6d6655470e85c42f870dd20792865
https://doi.org/10.1016/s1262-3636(16)30154-9
Zobrazit plný text záznamu
10
Akademický článek
Microglial activation induces nitric oxide signalling and alters protein S‐nitrosylation patterns in extracellular vesicles.
Autor: Vassileff, Natasha1 (AUTHOR), Spiers, Jereme G.1,2,3 (AUTHOR), Bamford, Sarah E.4 (AUTHOR), Lowe, Rohan G. T.5 (AUTHOR), Datta, Keshava K.5 (AUTHOR), Pigram, Paul J.4 (AUTHOR), Hill, Andrew F.1,6 (AUTHOR) andy.hill@vu.edu.au
Publikováno v: Journal of Extracellular Vesicles. Jun2024, Vol. 13 Issue 6, p1-16. 16p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje